Safety Study of Vx006 Vaccine in Solid Tumor Patients
NCT02289196
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
Vx-006: 0,5mg
DRUG:
Vx-006: 1mg
DRUG:
Vx-006: 5mg
DRUG:
Vx-006: 10mg
Sponsor
Vaxon Biotech